Dyslipidemia: Contemporary Evaluation and Management eReport
Latest Publications

TOTAL DOCUMENTS

(FIVE YEARS 0)

H-INDEX

(FIVE YEARS 0)

Published By American Society Of Health-System Pharmacists

9781585284719

Latest Documents Most Cited Documents Contributed Authors Related Sources Related Keywords

Should All Patients with an Acute Coronary Event or at High CHD Risk Be Started on High-Dose Statin Therapy?

Dyslipidemia: Contemporary Evaluation and Management eReport ◽

10.37573/9781585284719.034 ◽

2014 ◽

pp. 22-22

Keyword(s):

Statin Therapy ◽

Coronary Event ◽

High Dose ◽

Acute Coronary Event ◽

Chd Risk

What LDL-C Level Is Too Low?

Dyslipidemia: Contemporary Evaluation and Management eReport ◽

10.37573/9781585284719.033 ◽

2014 ◽

pp. 21a-22

Table 1-11. Relative LDL-Lowering Efficacy of Statin and Statin-Based Therapies

Dyslipidemia: Contemporary Evaluation and Management eReport ◽

10.37573/9781585284719.021 ◽

2014 ◽

pp. 17-17

Omega-3 Fatty Acids

Dyslipidemia: Contemporary Evaluation and Management eReport ◽

10.37573/9781585284719.020 ◽

2014 ◽

pp. 17-17

Keyword(s):

Fatty Acids ◽

Omega 3 Fatty Acids ◽

Omega 3

Nicotinic Acid

Dyslipidemia: Contemporary Evaluation and Management eReport ◽

10.37573/9781585284719.019 ◽

2014 ◽

pp. 16a-16a

Keyword(s):

Nicotinic Acid

Table 1-9. Risk Indicators (Other than Major ASCVD Risk Factors) that Might Be Considered for Risk Refinement

Dyslipidemia: Contemporary Evaluation and Management eReport ◽

10.37573/9781585284719.013 ◽

2014 ◽

pp. 11c-11c

Keyword(s):

Risk Factors ◽

Risk Indicators ◽

Ascvd Risk ◽

Risk Refinement

National Lipid Association Recommendations

Dyslipidemia: Contemporary Evaluation and Management eReport ◽

10.37573/9781585284719.012 ◽

2014 ◽

pp. 12-12

Clinical Presentation, Diagnosis, and Disease Classification

Dyslipidemia: Contemporary Evaluation and Management eReport ◽

10.37573/9781585284719.005 ◽

2014 ◽

pp. 9-9

Keyword(s):

Clinical Presentation ◽

Disease Classification

What Is the Best Strategy to Manage Residual Cardiovascular Risk?

Dyslipidemia: Contemporary Evaluation and Management eReport ◽

10.37573/9781585284719.032 ◽

2014 ◽

pp. 21-21

Keyword(s):

Cardiovascular Risk ◽

Residual Cardiovascular Risk

What Drug-Drug Interactions Impact Statin Therapy?

Dyslipidemia: Contemporary Evaluation and Management eReport ◽

10.37573/9781585284719.027 ◽

2014 ◽

pp. 19-19

Keyword(s):

Drug Interactions ◽

Statin Therapy

Dyslipidemia: Contemporary Evaluation and Management eReportLatest Publications

TOTAL DOCUMENTS

H-INDEX

Published By American Society Of Health-System Pharmacists

Should All Patients with an Acute Coronary Event or at High CHD Risk Be Started on High-Dose Statin Therapy?

What LDL-C Level Is Too Low?

Table 1-11. Relative LDL-Lowering Efficacy of Statin and Statin-Based Therapies

Omega-3 Fatty Acids

Nicotinic Acid

Table 1-9. Risk Indicators (Other than Major ASCVD Risk Factors) that Might Be Considered for Risk Refinement

National Lipid Association Recommendations

Clinical Presentation, Diagnosis, and Disease Classification

What Is the Best Strategy to Manage Residual Cardiovascular Risk?

What Drug-Drug Interactions Impact Statin Therapy?

Dyslipidemia: Contemporary Evaluation and Management eReport
Latest Publications